Golden Sunrise Nutraceutical, Inc.
LAST UPDATED: JULY 31, 2020CASE STATUS: PendingFederal Trade Commission, Plaintiff, v. Golden Sunrise Nutraceutical, Inc., a corporation; Golden Sunrise Pharmaceutical, Inc., a corporation; Huu Tieu, individually and as an officer of Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc.; and Stephen Meis, individually and as an officer of Golden Sunrise Nutraceutical, Inc.; Defendants.
FTC MATTER/FILE NUMBER:
202 3146CIVIL ACTION NUMBER:
Federal InjunctionsFEDERAL COURT: Eastern District of California
In July 2020, the Federal Trade Commission filed a complaint in federal court against the California-based marketers and promoters of bogus treatments for serious medical conditions. The defendants are two corporations headquartered in Porterville, California, and two of their executives: Huu Tieu, President and CEO of both companies; and Stephen Weis, Medical Director and board member of Golden Sunrise Nutraceutical. The complaint alleges that defendants have promoted and sold a variety of products through “plans of care” ranging in price from $23,000 to $200,000, which falsely claim to treat or cure COVID-19, cancer, Parkinson’s disease, etc.